Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03244488 · ClinicalTrials.gov registry record
Mental Ability Challenge Study in Adults With and Without HIV
A clinical trial of Cognitive Impairment and HIV-1-infection, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03244488: Completed study of Cognitive Impairment and HIV-1-infection, sponsored by Vanderbilt University Medical Center.
NCT03244488 is a study of Cognitive Impairment and HIV-1-infection that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 22 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03244488, a study of Cognitive Impairment and HIV-1-infection, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
It is estimated that by 2016, nearly 50% of HIV-positive individuals in the US will be aged 50 or older, and up to 60% of those will experience some degree of cognitive impairment as they age. The purpose of this study is to evaluate the contribution of the neuronal cholinergic receptor system to the cognitive impairments seen in adults aging with chronic HIV Infection. By using anti-cholinergic challenge drugs to reversibly "stress" cognitive functioning, the investigators hope to understand whether the presence of the HIV virus in the brain impairs the neural system necessary for normal cognition, more than would be expected from normal cognitive aging.
Primary Outcome
Cognitive performance will be more significantly impaired by study medications in HIV-positive participants relative to HIV-negative participants, indicating impairment of cholinergic neurotransmitter system.
Conditions Studied
Interventions
- DRUG Scopolamine Injectable Product
- DRUG Mecamylamine Pill
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-12 |
What the finished NCT03244488 record still lists
NCT03244488 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Scopolamine Injectable Product is the first listed.
NCT03244488 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03244488 about?
NCT03244488 is a clinical study titled "Mental Ability Challenge Study in Adults With and Without HIV". It is estimated that by 2016, nearly 50% of HIV-positive individuals in the US will be aged 50 or older, and up to 60% of those will experience some degree of cognitive impairment as they age. The purpose of this study is to evaluate the contribution of the neuronal cholinergic receptor system to th...
What is the current status of trial NCT03244488?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2015-12. Estimated completion is 2018-12.
What conditions does trial NCT03244488 study?
This clinical trial studies the following conditions: Cognitive Impairment, HIV-1-infection, Memory Impairment, Aging, Premature, HIV Associated Cognitive Motor Complex.
What interventions are being tested in trial NCT03244488?
The interventions under investigation include: Scopolamine Injectable Product (DRUG), Mecamylamine Pill (DRUG).
Who is sponsoring clinical trial NCT03244488?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03244488 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03244488's enrollment target sits among peer trials
22 92nd of 105 higher than 14 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia